GF
JSPR icon

Gries Financial’s Jasper Therapeutics JSPR Stock Holding History

Gries Financial’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,385
Closed -$18.8K – 278
2023
Q4 		$18.8K Hold
2,385
– – ﹤0.01% 214
2023
Q3 		$16.7K Hold
2,385
– – ﹤0.01% 179
2023
Q2 		$32.7K Buy
+2,385
New +$35.4K 0.01% 158

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Gries Financial's JSPR Position: Q1 2024 in Review

Gries Financial sold out of Jasper Therapeutics (JSPR) in Q1 2024, closing a stake of 2,385 shares — an estimated $18.8K sold.

Gries Financial first reported a position in JSPR in Q2 2023 and held it in 3 quarters. The position peaked at $32.7K in Q2 2023. 61 funds tracked by Wall St. Rank hold JSPR as of Q1 2024.

  • Gries Financial reported no remaining Jasper Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Gries Financial sold 2,385 Jasper Therapeutics shares in Q1 2024, an estimated $18.8K.
  • Gries Financial first reported a position in Jasper Therapeutics in Q2 2023 and held it in 3 quarters.
  • Gries Financial's Jasper Therapeutics position peaked at $32.7K in Q2 2023.
  • 61 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2024.

Based on Gries Financial's 13F filing for Q1 2024, filed 15 May 2024.